Greenwich LifeSciences(GLSI)

Focus: Greenwich LifeSciences is a public biotechnology company focused on immunotherapy for cancer, specifically oncology. The company is in early-stage development with a single Phase 3 trial in breast cancer.

Oncology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Greenwich LifeSciences

AI assessmentNot Hiring

No open roles listed right now. Follow Greenwich LifeSciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Placebo

Breast Cancer

Phase 3

Clinical Trials (1)

NCT05232916Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Phase 3

Help build intelligence for Greenwich LifeSciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on a focused, late-stage oncology program with a Phase 3 trial actively enrolling in breast cancer
Public company status provides liquidity and potential equity upside if Phase 3 succeeds
Lean organization structure allows for direct impact on clinical and regulatory strategy

Watch Out For

No active hiring (0 open positions) signals contraction or full team capacity despite single ongoing trial
Severe cash burn: $8M R&D spend in FY 2024 with only $7M cash remaining and cumulative losses exceeding $8.8M, creating runway risk within 12 months
Single-program pipeline with no Phase 1 or Phase 2 programs limits career optionality if Phase 3 fails

Generated by Claude from Greenwich LifeSciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Oncology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline

Financials (FY2024)

R&D Spend

$8M19%

Net Income

-$9M

Cash

$7M

Source: SEC 10-K Filing